Galectin Therapeutics (GALT) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'GALT	'
Entity Registrant Name	'GALECTIN THERAPEUTICS INC	'
Entity Central Index Key	'0001133416	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	18,311,968

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$9,715	$9,364
Prepaid expenses and other current assets	27	153
Total current assets	9,742	9,517
Property and equipment, net	5	8
Other long term assets	6	6
Intangible assets, net	24	30
Total assets	9,777	9,561
Current liabilities:	'	'
Accounts payable	377	397
Accrued expenses	1,226	1,161
Accrued dividends payable	'	80
Total current liabilities	1,603	1,638
Other long-term liabilities	1	6
Total liabilities	1,604	1,644
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 8,001,000 designated at September 30, 2013 and December 31, 2012	'	'
Series A 12% convertible preferred stock; 5,000,000 shares authorized, 1,562,500 issued and outstanding at September 30, 2013 and December 31, 2012	632	632
Common stock, $0.001 par value; 50,000,000 shares authorized at September 30, 2013 and December 31, 2012, 17,650,977 and 16,060,853 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	18	16
Additional paid-in capital	99,500	80,535
Deficit accumulated during the development stage	-98,850	-80,018
Total stockholders' equity	1,300	1,165
Total liabilities, redeemable convertible preferred stock and stockholders' equity	9,777	9,561
Series B-1 12% redeemable convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock, value	1,710	1,698
Series B-2 12% redeemable convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock, value	3,058	2,900
Series C super dividend convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock, value	$2,105	$2,154

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Convertible preferred stock, redemption value	$241,000	'
Undesignated stock, par value	$0.01	$0.01
Undesignated stock, shares authorized	20,000,000	20,000,000
Undesignated stock, shares designated	8,001,000	8,001,000
Series A 12% convertible preferred stock, shares authorized	5,000,000	5,000,000
Series A 12% convertible preferred stock, issued	1,562,500	1,562,500
Series A 12% convertible preferred stock, outstanding	1,562,500	1,562,500
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	17,650,977	16,060,853
Common stock, outstanding	17,650,977	16,060,853
Series B-1 12% redeemable convertible preferred stock	'	'
Convertible preferred stock, shares authorized	900,000	900,000
Convertible preferred stock, issued	900,000	900,000
Convertible preferred stock, outstanding	900,000	900,000
Convertible preferred stock, redemption value	1,800,000	'
Convertible preferred stock, liquidation value	1,800,000	'
Series B-2 12% redeemable convertible preferred stock	'	'
Convertible preferred stock, shares authorized	2,100,000	2,100,000
Convertible preferred stock, issued	2,100,000	2,100,000
Convertible preferred stock, outstanding	2,100,000	2,100,000
Convertible preferred stock, redemption value	4,200,000	'
Convertible preferred stock, liquidation value	4,200,000	'
Series C super dividend convertible preferred stock	'	'
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, issued	215	220
Convertible preferred stock, outstanding	215	220
Convertible preferred stock, redemption value	5,013,000	'
Convertible preferred stock, liquidation value	$2,150,000	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended		159 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating expenses:	'	'	'	'	'
Research and development	$1,192	$1,409	$4,293	$3,525	$31,903
General and administrative	2,353	1,487	5,007	3,992	52,043
Total operating expenses	3,545	2,896	9,300	7,517	83,946
Total operating loss	-3,545	-2,896	-9,300	-7,517	-83,946
Other income (expense):	'	'	'	'	'
Interest income	3	7	11	18	829
Interest expense	'	'	'	'	-4,451
Change in fair value of convertible debt instrument	'	'	'	'	-3,426
Change in fair value of warrant liabilities	'	'	'	'	9,022
Other income	'	200	'	200	691
Total other income (expense)	3	207	11	218	2,665
Net loss	-3,542	-2,689	-9,289	-7,299	-81,281
Preferred stock dividends	-123	-238	-613	-702	-4,848
Preferred stock accretion	-58	-58	-171	-172	-4,216
Modification of warrants	'	'	-8,763	'	-8,763
Net loss applicable to common stockholders	($3,723)	($2,985)	($18,836)	($8,173)	($99,108)
Net loss per common share - basic and diluted	($0.22)	($0.19)	($1.15)	($0.55)	'
Weighted average common shares outstanding - basic and diluted	16,988	15,822	16,438	14,851	'

Consolidated_Statement_Of_Chan

Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' (Deficit) Equity (USD $)

Total

Series A 12% Convertible Preferred Stock

Series C super dividend convertible preferred stock

Series B-1 12% redeemable convertible preferred stock

Series B-2 12% redeemable convertible preferred stock

Series C super dividend convertible preferred stock

Series A 12% Convertible Preferred Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

In Thousands, except Share data

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Series A 12% Convertible Preferred Stock

Series B-1 12% redeemable convertible preferred stock

Series B-2 12% redeemable convertible preferred stock

Series C super dividend convertible preferred stock

USD ($)

Series A 12% Convertible Preferred Stock

Series B-1 12% redeemable convertible preferred stock

Series B-2 12% redeemable convertible preferred stock

Series C super dividend convertible preferred stock

USD ($)

Series A 12% Convertible Preferred Stock

Series B-1 12% redeemable convertible preferred stock

Series B-2 12% redeemable convertible preferred stock

Series C super dividend convertible preferred stock

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Beginning Balance at Dec. 31, 2012

$1,165

'

'

$1,698

$2,900

$2,154

$632

$16

'

'

'

'

$80,535

'

'

'

'

($80,018)

'

'

'

'

Beginning Balance (in shares) at Dec. 31, 2012

'

'

'

900,000

2,100,000

220

1,562,500

16,060,853

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accretion of Series B redeemable convertible preferred stock

-130

'

'

12

118

'

'

'

'

'

'

'

'

'

'

'

'

-130

'

'

'

'

Accretion of beneficial conversion feature for Series B-2

-40

'

'

'

40

'

'

'

'

'

'

'

'

'

'

'

'

-40

'

'

'

'

Issuance of common stock (in shares)

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

3,000

'

'

'

'

'

'

1

'

'

'

'

2,999

'

'

'

'

'

'

'

'

'

Convertible preferred stock dividend (in shares)

'

'

'

'

'

'

'

'

25,038

29,689

69,580

23,848

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock dividend

'

47

33

'

'

'

'

'

'

'

'

'

'

149

123

291

127

'

-102

-123

-291

-94

Conversion of Series C to common stock (in shares)

'

'

'

'

'

-5

'

8,475

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Series C to common stock

49

'

'

'

'

-49

'

'

'

'

'

'

49

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of options (in shares)

156,349

'

'

'

'

'

'

156,341

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of options

184

'

'

'

'

'

'

'

'

'

'

'

184

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

'

'

777,153

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants

3,005

'

'

'

'

'

'

1

'

'

'

'

3,004

'

'

'

'

'

'

'

'

'

Modification of warrants

-8,763

'

'

'

'

'

'

'

'

'

'

'

8,763

'

'

'

'

-8,763

'

'

'

'

Stock-based compensation expense

3,276

'

'

'

'

'

'

'

'

'

'

'

3,276

'

'

'

'

'

'

'

'

'

Net loss

-9,289

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,289

'

'

'

'

Ending Balance at Sep. 30, 2013

$1,300

'

'

$1,710

$3,058

$2,105

$632

$18

'

'

'

'

$99,500

'

'

'

'

($98,850)

'

'

'

'

Ending Balance (in shares) at Sep. 30, 2013

'

'

'

900,000

2,100,000

215

1,562,500

17,650,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	9 Months Ended		159 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($9,289,000)	($7,299,000)	($81,281,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	9,000	5,000	564,000
Stock-based compensation expense	3,276,000	2,170,000	15,650,000
Non-cash interest expense	'	'	4,279,000
Change in fair value of convertible debt instrument	'	'	3,426,000
Change in fair value of warrant liabilities	'	'	-9,022,000
Write off of intangible assets	'	'	351,000
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other assets	126,000	68,000	-30,000
Accounts payable and accrued expenses	45,000	-693,000	1,671,000
Other long-term liabilities	-5,000	'	1,000
Net cash used in operating activities	-5,838,000	-5,749,000	-64,391,000
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchases of property and equipment	'	-2,000	-431,000
Change in restricted cash	'	10,000	'
Increase in patents costs and other assets	'	'	-404,000
Net cash provided by (used in) investing activities	'	8,000	-835,000
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Net proceeds from issuance of common stock and warrants	3,000,000	10,403,000	42,093,000
Net proceeds from issuance of convertible debt instruments	'	'	10,621,000
Repayment of convertible debt instruments	'	'	-1,641,000
Proceeds from exercise of common stock warrants and options	3,189,000	'	14,482,000
Proceeds from shareholder advances	'	'	9,000
Net cash provided by financing activities	6,189,000	10,403,000	74,941,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	351,000	4,662,000	9,715,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	9,364,000	6,397,000	'
CASH AND CASH EQUIVALENTS, END OF PERIOD	9,715,000	11,059,000	9,715,000
SUPPLEMENTAL DISCLOSURE - Cash paid for interest	'	'	114,000
NONCASH FINANCING ACTIVITIES:	'	'	'
Issuance of equity warrants in connection with equity offerings	'	4,445,000	9,482,000
Conversion of accrued expenses into common stock	'	26,000	329,000
Conversion and redemption of convertible notes and accrued interest into common stock	'	'	12,243,000
Conversion of extension costs related to convertible notes into common stock	'	'	171,000
Payment of preferred stock dividends in common stock	694,000	782,000	4,849,000
Issuance of warrants to induce conversion of notes payable	'	'	503,000
Issuance of stock to acquire Pro-Pharmaceuticals-NV	'	'	107,000
Series A 12% Convertible Preferred Stock	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Net proceeds from issuance of convertible preferred stock and related warrants	'	'	1,691,000
Series B-1 12% redeemable convertible preferred stock	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Net proceeds from issuance of redeemable convertible preferred stock and related warrants	'	'	1,548,000
Series B-2 12% redeemable convertible preferred stock	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Net proceeds from issuance of redeemable convertible preferred stock and related warrants	'	'	3,935,000
Series C super dividend convertible preferred stock	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Net proceeds from issuance of convertible preferred stock and related warrants	'	'	$2,203,000

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Basis of Presentation	'
	1	Basis of Presentation
	Galectin Therapeutics Inc. (the “Company”) is a development-stage company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These therapeutic candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic functions. These compounds also may have application for drugs to treat other diseases and chronic health conditions.
	The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of September 30, 2013 and the results of its operations for the three and nine months ended September 30, 2013 and 2012 and the cumulative period from inception (July 10, 2000) through September 30, 2013 and its cash flows for the nine months ended September 30, 2013 and 2012, and for the cumulative period from inception (July 10, 2000) to September 30, 2013. Such adjustments, other than nonrecurring adjustments that have been separately disclosed, are of a normal, recurring nature. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2012.
	The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future as is develops its therapeutic candidates. At September 30, 2013, the Company had $9,715,000 of unrestricted cash and cash equivalents available to fund future operations. Subsequent to September 30, 2013, the Company received $1,580,600 from the exercise of warrants and stock options for 556,667 shares of common stock. Additionally subsequent to September 30, 2013, the Company had issued 50,643 shares of its common stock through its At Market issuance program (see Note 9) at an average price of $10.82 per share resulting in net proceeds of approximately $531,000. The Company believes that with the cash on hand at September 30, 2013 and the cash received subsequent to quarter end, there is sufficient cash to fund operations into the third quarter of 2014. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. The Company has developed plans, including cost containment efforts in the event that such financing cannot be realized by the Company. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	As shown in the condensed consolidated financial statements, the Company incurred cumulative net losses applicable to common stockholders of $99.1 million for the cumulative period from inception (July 10, 2000) through September 30, 2013. The Company’s net losses have resulted principally from costs associated with (i) research and development expenses, including clinical trial costs, (ii) general and administrative activities and (iii) the Company’s financing transactions including interest, dividend payments, and the costs related to fair value accounting for the Company’s convertible debt instruments. As a result of planned expenditures for future research, discovery, development and commercialization activities and potential legal cost to protect its intellectual property, the Company expects to incur additional losses and use additional cash in its operations for the foreseeable future. Through September 30, 2013, the Company had raised a net total of $74.9 million in capital through sale and issuance of common stock, common stock purchase warrants, convertible preferred stock and debt securities in public and private offerings. From inception (July 10, 2000) through September 30, 2013, the Company used cash of $64.4 million in its operations.
	The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company began trading on The NASDAQ Capital Market under the symbol GALT. Immediately prior to March 23, 2012, the Company was traded on the Over-the Counter Bulletin Board (“OTCBB”) under the symbol GALT.OB.
	The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Accrued Expenses	'
	2	Accrued Expenses
	Accrued expenses consist of the following:
			September 30,		December 31,
			2013		2012
			(in thousands)
	Legal and accounting fees		$	115	$	109
	Accrued compensation			57		42
	Severance agreement (Note 8)			1,000		1,000
	Other			54		10
	Total		$	1,226	$	1,161

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
	3	Stock-Based Compensation
	Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013		2012
			(in thousands)
	Research and development		$	335		$	248		$	865	$	756
	General and administrative			1,473			571			2,411		1,414
	Total stock-based compensation expense		$	1,808		$	819		$	3,276	$	2,170
	The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through September 30, 2013:
			Shares			Weighted Average
						Exercise Price
	Outstanding, December 31, 2012			3,539,961		$	5.66
	Granted			425,426			3.89
	Exercised			(156,349	)		1.69
	Options forfeited/cancelled			(302,041	)		17.16
	Outstanding, September 30, 2013			3,507,005		$	4.59
	As of September 30, 2013, there was $5,086,000 of unrecognized compensation related to 1,515,137 unvested options, which is expected to be recognized over a weighted–average period of approximately 4.2 years. The weighted-average grant date fair value for options granted during the three and nine months ended September 30, 2013 was $3.55 and $3.17, respectively. The weighted-average grant date fair value for options granted during the three and nine months ended September 30, 2012 was $1.89 and $1.72, respectively.
	The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:
						Cumulative
						Period from
			Nine Months Ended			Inception
			September 30,			(July 10, 2000) to
						September 30,
			2013			2013
	Risk-free interest rate			1.17	%		1.75	%
	Expected life of the options			5.3 years			5.2 years
	Expected volatility of the underlying stock			115	%		119	%
	Expected dividend rate			0	%		0	%
	On September 26, 2013, the Company modified certain vested stock options held by a former member of the Company’s board of directors. The individual left the board on May 23, 2013. The modification extended the contractual period of exercise of 103,158 stock options until the end of their original terms instead of such options expiring 3 months after service on the board ended. As a result, the Company recorded a non-cash charge of $930,000 related to the modification in the quarter ended September 30, 2013.

Common_Stock_Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2013
Common Stock Warrants	'
	4	Common Stock Warrants
	The following table summarizes the common stock warrant activity from December 31, 2012 through September 30, 2013:
			Shares			Weighted Average
						Exercise Price
	Outstanding, December 31, 2012			7,424,241		$	3.71
	Granted			5,000			2.65
	Exercised			(831,212	)		4.17
	Forfeited/cancelled			(50,000	)		3
	Outstanding, September 30, 2013			6,548,029		$	3.65
	Warrants Modification
	On May 6, 2013, the Company modified the terms of the Class A-2 and Class B warrants that were originally issued to the 10X Fund with the Series B Preferred Stock offering. The Class B warrants were modified to allow for the cashless exercise of all 4,000,000 outstanding Class B warrants. Previously, only half of the Class B warrants allowed for cashless exercise. The Class A-2 warrants for the purchase of 1,000,000 shares of common and all of the Class B warrants had their exercisable life extended by an additional five years. In exchange for these modifications, the 10X Fund agreed to a future amendment of the Company’s Series B certificate of designation to remove the redemption provision such that the Series B Preferred Stock will no longer be redeemable, if and when the Company will no longer be required to issue Dr. Platt a promissory note as may currently be required under the separation agreement (see Note 8). Should the Company amend their Series B certificate of designation in the future as described above, the Company will be required at that time to evaluate whether such amendment is to be accounted for as a modification or an extinguishment of the Company’s Series B Preferred Stock. The Company has accounted for the modified terms of the Class A-2 and Class B warrants pursuant to ASC 718, Stock Compensation, whereby the Company has recognized a charge for the change in fair value of the warrants immediately before and immediately after the modification. For the three and six month period ended June 30, 2013, the Company recognized a charge of $8,763,000 related to the extension of the 5,000,000 warrants. The following assumptions were used to value the extension of the warrants immediately before and immediately after the modification: a) immediately before the modification—an expected life range of 0.77 to 2.01 years, volatility range of 77% to 96%, risk free interest rate range of 0.11% to 0.22% and zero dividends and; b) immediately following the modification—an expected life range of 5.78 to 7.02 years, volatility range of 113% to 122%, risk free interest rate range of 0.74% to 1.19% and zero dividends.
	Consultant Warrants
	In January 2013, the Company entered into an agreement with a consultant that provided for the grant of warrants for the purchase of 5,000 shares of common stock at an exercise price of $2.65 per share. The following assumptions were used to value the warrants: an expected life of 3 years, volatility of 87%, risk free interest rate of 0.42% and zero dividends. The Company recognized an expense of $7,000 related to these warrants at the time of the grant as they were vested at issuance. The warrants were exercised in September 2013.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2013
Fair Value of Financial Instruments	'
	5	Fair Value of Financial Instruments
	The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximates their carrying value due to their short-term nature. Included in cash and cash equivalents, as of September 30, 2013 and December 31, 2012, the Company had $0 and $583,000, respectively invested in money market funds which had calculated net asset values and were therefore classified as Level 2. There were no level 3 assets held at fair value at September 30, 2013 or December 31, 2012.

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2013
Loss Per Share	'
	6	Loss Per Share
	Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share. Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:
			September 30, 2013		September 30, 2012
			(shares)		(shares)
	Warrants to purchase shares of common stock			6,548,029		7,424,241
	Options to purchase shares of common stock			3,507,005		3,541,630
	Shares of common stock issuable upon conversion of preferred stock			2,618,772		2,627,110
				12,673,806		13,592,981

Common_Stock_and_Warrant_Offer

Common Stock and Warrant Offering and Reverse Split	9 Months Ended
	Sep. 30, 2013
Common Stock and Warrant Offering and Reverse Split	'
	7	Common Stock and Warrant Offering and Reverse Split
	On March 22, 2012, the Company entered into an underwriting agreement relating to the offer and sale of 1,159,445 units (the “Units”) of the Company. Each unit consisted of two shares of Common Stock and one warrant to purchase one share of Common Stock. Pursuant to the underwriting agreement, the Company granted the underwriters a 45-day option to purchase up to an additional 173,916 Units to cover over-allotments, which they exercised on March 26, 2012. The public offering price for each Unit was $9.00. Each warrant has an initial exercise price of $5.63 per share, is exercisable upon separation of the Units and expires on March 28, 2017.
	On March 28, 2012, the Company sold and issued 1,333,361 Units (2,666,722 shares of common stock and related $5.63 warrants to purchase 1,333,361 shares of common stock) for gross proceeds of $12.0 million (net cash proceeds of $10,403,000 after the underwriting discount and offering costs). The warrants were valued at $4,445,000 as of the issuance date of March 28, 2012, using the closing price of $4.20, a life of 5 years, a volatility of 119% and a risk free interest rate of 1.05%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.
	On March 28, 2012, in connection with this underwritten financing as per the underwriting agreement, the Company issued a total of 46,378 common stock purchase warrants to the underwriters. These warrants expire May 2, 2016, have an exercise price of $5.63 per share, and are exercisable beginning 1 year from March 22, 2012 (the date of the underwriting agreement). These warrants were valued at $143,000 as of the date of issuance (March 28, 2012), using the closing price of $4.20, life of 4.1 years, volatility of 117% and risk free interest rate of 0.78. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity”, the Company has determined that these warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.
	Effective as of March 23, 2012, and in connection with the pricing of the offering of Units, the Company effected a one-for-six reverse split of its Common Stock. Per the terms of the reverse split, all fractional shares were rounded up.
	On August 16, 2013, the Company issued 500,000 shares of its common stock for proceeds of $3,000,000 to a single investor pursuant to a private placement. There were no warrants or placement fees associated with this transaction.

Commitments_Contingencies_and_

Commitments, Contingencies and Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Commitments, Contingencies and Legal Proceedings	'
	8	Commitments, Contingencies and Legal Proceedings
	Agreement with CTI for Phase I Clinical Trial
	On February 1, 2013, the Company entered into an Amended and Restated Master Services Agreement (the “Agreement”) with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, “CTI”), whereby CTI is assisting the Company in the design, development and conduct of one or more clinical research studies from time to time. All work performed by CTI for the Company is being conducted pursuant to the terms of work orders that describe the specific obligations undertaken by CTI with respect to any particular clinical research study sponsored or conducted by the Company. Unless otherwise terminated sooner in accordance with the terms of the Agreement, the Agreement will be effective until January 31, 2018.
	On February 1, 2013, the Company entered into a work order (the “Work Order”) with CTI in accordance with the terms of the Agreement. The Work Order provides that CTI will provide services with respect to the Company’s Phase I Clinical Trial to evaluate the safety of the Company’s drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (“NASH”) with advanced hepatic fibrosis. CTI is providing the following services, amongst others, with respect to the Work Order: reviewing and providing notices regarding IND safety reports, selecting investigators and monitors for the study, informing investigators of new observations, monitoring the progress of the study and reviewing ongoing investigations, keeping certain records, inspecting the Company’s records and reports, and disposing of any unused supply of the investigational drug.
	The Work Order provides for CTI’s anticipated involvement in the study from February 1, 2013 until March 31, 2014. The estimated budget for the Work Order is $2,155,000, which is subject to change as necessary, with payments made throughout the term of the project as the work is performed. During the three and nine months ended September 30, 2013, the Company recognized $239,000 and $1,329,000 of expenses related to this agreement for services performed.
	The Agreement or any work order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. In addition, the Agreement may be terminated by either party immediately if the other party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has filed against it (and does not obtain a dismissal within ninety (90) days) a petition of bankruptcy, or has a receiver appointed for it or a substantial part of its assets, among other reasons. Further, the Agreement or any relevant work order may be terminated immediately by written notice from the Company, in the following circumstances: (1) the FDA withdraws authorization and approval to conduct a study; or (2) the Company reasonably determines that for medical, clinical or patient safety reasons, a study should terminate immediately. In addition, either party may terminate the Agreement or any work order for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period.
	Drug Discovery Program with the University of Georgia
	In February 2013, the Company established a collaborative drug discovery program at the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders. The term of the agreement is effective through December 31, 2013, for which the Company will provide funding of $154,000 during the period. The Company has paid $154,000 related to this program through September 30, 2013. This agreement may be terminated by either party upon 90 days notice.
	Separation Agreement
	In February 2009, the Company entered into a Separation Agreement in connection with the resignation of David Platt, Ph.D., the Company’s former Chief Executive Officer and Chairman of the Board of Directors. The Separation Agreement provides for the deferral of a $1.0 million separation payment due to Dr. Platt upon the earlier occurrence of any of the following milestone events: (i) the approval by the Food and Drug Administration for a new drug application (“NDA”) for any drug candidate or drug delivery candidate based on the Company’s GM-CT-01 technology (whether or not such technology is patented), in which case Dr. Platt is also entitled to a fully vested 10-year cashless-exercise stock option to purchase at least 83,334 shares of common stock at an exercise price not less than the fair market value of the common stock determined as of the date of grant; (ii) consummation of a transaction with a pharmaceutical company expected to result in at least $10.0 million of equity investment or $50 million of royalty revenue to the Company, in which case Dr. Platt is also entitled to stock options on the same terms to purchase at least 50,000 shares of common stock; or (iii) the renewed listing of the Company’s securities on a national securities exchange and the achievement of a market capitalization of $100 million. Payment upon the events (i) and (iii) may be deferred up to six months, and if the Company has insufficient cash at the time of any of such events, it may issue Dr. Platt a secured promissory note for such amount. If the Company files a voluntary or involuntary petition for bankruptcy, whether or not a milestone event has occurred, such event shall trigger the obligation to pay the $1.0 million with the result that Dr. Platt may assert a claim for such obligation against the bankruptcy estate. During 2011, when it became probable that the Company could be relisted on a national securities exchange and eventually reach a market capitalization of $100 million, the Company recognized the $1.0 million severance payment due to Dr. Platt and it is included in accrued expenses at September 30, 2013 and December 31, 2012.
	On May 2, 2012, Dr. Platt instituted an arbitration with the American Arbitration Association seeking the $1 million payment based on a claim that the milestone event in the Separation Agreement described in clause (iii) above had occurred. Although the Company had listed its common stock on the Nasdaq Capital Markets as of March 22, 2012, the market capitalization since the listing had not reached $100 million when the arbitration was heard in October 2012. On November 1, 2012, the arbitrator denied Dr. Platt’s demand in all respects.
	On October 12, 2012, Dr. Platt commenced a lawsuit under the Massachusetts Wage Act against Dr. Traber and Mr. McGauley who in their capacities as the Company’s Chief Executive Officer and Chief Financial Officer respectively can be held individually liable under the Wage Act for non-payment of wages. The lawsuit is based on the facts and issues raised in the arbitration regarding the payment of the $1.0 million separation payment under the Separation Agreement, and other unspecified “wages”. The statute provides that a successful claimant may be entitled to multiple damages, interest and attorney’s fees. Although the Company is not a party to the lawsuit, it plans to indemnify Dr. Traber and Mr. McGauley consistent with its obligations under the by-laws and applicable law, believes the lawsuit is without merit, and intends a vigorous defense on their behalf. On April 29, 2013, the Court allowed Dr. Traber’s and Mr. McGauley’s motion to dismiss. Dr. Platt filed a Notice of Appeal to appeal the Court’s order allowing the defendants’ motion to dismiss.
	On March 29, 2013, the Company instituted arbitration before the American Arbitration Association, seeking to rescind or reform the Separation Agreement discussed above. The Company claims that Dr. Platt fraudulently induced the Company to enter into the Separation Agreement, breached his fiduciary duty to the Company, and was unduly enriched from his conduct. Along with removal of the $1.0 million milestone payment under the Separation Agreement, the Company is seeking repayment of all separation benefits paid to Dr. Platt to date. Depending on the outcome of the arbitration, the previously accrued $1.0 million could be reversed. This arbitration has been scheduled for May 2014; however, the ultimate outcome is uncertain and there is no guarantee that the Company will be successful in this demand.
	On August 1, 2013, the market capitalization of the Company’s common stock exceeded $100 million and the Company received a letter dated October 1, 2013, demanding payment of the $1 million. As described in the preceding paragraph, the Company had previously instituted an arbitration against Dr. Platt seeking to rescind the Separation Agreement, including the milestone payment provision. The Company expects to delay payment for at least six months under the terms of the Separation Agreement.
	Series C Post Conversion Dividend Rights
	In January 2013, 5 shares of the Company’s Series C Super Dividend Convertible Preferred Stock (“Series C”) were converted into 8,475 shares of common stock (consisting of 8,334 shares of common stock for principal and 141 shares for accrued interest at the time of the conversion) which also resulted in the issuance of 5 Series C post-conversion dividend rights (“Dividend Rights”). Under the terms of the Series C, the Dividend Rights entitle the holder only to dividend payments based on actual sales of GM-CT-01 and will not participate in the 6% dividend payable on outstanding shares of Series C following a conversion to common stock. At September 30, 2013, there are a total of 10 outstanding Dividend Rights which were determined to have a de minimis value, because payment of a dividend for the Dividend Rights is considered improbable at this time and the Company has not recorded a liability related to the Dividend Rights. The Company will continue to evaluate and assess the Dividend Rights for each reporting period. At September 30, 2013, the Dividend Rights had a redemption value of $241,000.
	Other Legal Proceedings
	The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable, except as noted above. There has been no change in the matters reported in our Annual Report on Form 10-K for the year ended December 31, 2012.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events	'
	9	Subsequent Events
	On October 16, 2013 and November 1, 2013, the 10X Fund exercised 300,000 and 200,000 respectively, Class A-2 stock purchase warrants at $3.00 per share for total proceeds to the Company of $1,500,000.
	On October 25, 2013, the Company entered into an At Market Issuance Sales Agreement (the “At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the At Market Agreement. Subsequent to September 30, 2013, the Company had issued 50,643 shares of its common stock through its At Market issuance program at an average price of $10.82 per share resulting in net proceeds of approximately $531,000.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses	'
	Accrued expenses consist of the following:
		September 30,		December 31,
		2013		2012
		(in thousands)
	Legal and accounting fees	$	115	$	109
	Accrued compensation		57		42
	Severance agreement (Note 8)		1,000		1,000
	Other		54		10
	Total	$	1,226	$	1,161

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants	'
	Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
		(in thousands)
	Research and development	$	335		$	248		$	865	$	756
	General and administrative		1,473			571			2,411		1,414
	Total stock-based compensation expense	$	1,808		$	819		$	3,276	$	2,170
Summary of Stock Option Activity	'
	The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2012 through September 30, 2013:
		Shares			Weighted Average
					Exercise Price
	Outstanding, December 31, 2012		3,539,961		$	5.66
	Granted		425,426			3.89
	Exercised		(156,349	)		1.69
	Options forfeited/cancelled		(302,041	)		17.16
	Outstanding, September 30, 2013		3,507,005		$	4.59
Weighted Average Assumptions Used to Determine Fair Value of Options Granted	'
	The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:
					Cumulative
					Period from
		Nine Months Ended			Inception
		September 30,			(July 10, 2000) to
					September 30,
		2013			2013
	Risk-free interest rate		1.17	%		1.75	%
	Expected life of the options		5.3 years			5.2 years
	Expected volatility of the underlying stock		115	%		119	%
	Expected dividend rate		0	%		0	%

Common_Stock_Warrants_Tables

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Common Stock Warrant Activity	'
	The following table summarizes the common stock warrant activity from December 31, 2012 through September 30, 2013:
		Shares			Weighted Average
					Exercise Price
	Outstanding, December 31, 2012		7,424,241		$	3.71
	Granted		5,000			2.65
	Exercised		(831,212	)		4.17
	Forfeited/cancelled		(50,000	)		3
	Outstanding, September 30, 2013		6,548,029		$	3.65

Loss_Per_Share_Tables

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which Were Not Included in Calculation	'
	Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:
		September 30, 2013		September 30, 2012
		(shares)		(shares)
	Warrants to purchase shares of common stock		6,548,029		7,424,241
	Options to purchase shares of common stock		3,507,005		3,541,630
	Shares of common stock issuable upon conversion of preferred stock		2,618,772		2,627,110
			12,673,806		13,592,981

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended		9 Months Ended		159 Months Ended			2 Months Ended	1 Months Ended
	Mar. 22, 2012	Mar. 28, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2013	Oct. 25, 2013
										Subsequent Event	Subsequent Event
											At Market Agreement
Basis of Presentation [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Unrestricted cash and cash equivalents	'	'	$9,715,000	$11,059,000	$9,715,000	$11,059,000	$9,715,000	$9,364,000	$6,397,000	'	'
Proceeds from exercise of warrants	'	'	'	'	'	'	'	'	'	1,580,600	'
Issuance of common stock upon exercise of warrants	'	'	'	'	'	'	'	'	'	556,667	'
Common stock, issued	1,159,445	1,333,361	'	'	'	'	'	'	'	'	50,643
Average price per share	'	'	'	'	'	'	'	'	'	'	$10.82
Net proceeds from issuance of common stock	'	'	'	'	3,000,000	10,403,000	42,093,000	'	'	'	531,000
Net losses applicable to common stockholders	'	'	-3,723,000	-2,985,000	-18,836,000	-8,173,000	-99,108,000	'	'	'	'
Net total capital through sale and issuance of common stock and warrants	'	'	'	'	3,000,000	'	74,900,000	'	'	'	'
Net cash used in operating activities	'	'	'	'	($5,838,000)	($5,749,000)	($64,391,000)	'	'	'	'

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Feb. 28, 2009
In Thousands, unless otherwise specified
Schedule of Accrued Liabilities [Line Items]	'	'	'
Legal and accounting fees	$115	$109	'
Accrued compensation	57	42	'
Severance agreement (Note 8)	1,000	1,000	1,000
Other	54	10	'
Total	$1,226	$1,161	'

StockBased_Compensation_Expens

Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) (USD $)	3 Months Ended		9 Months Ended		159 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation expense	$1,808,000	$819,000	$3,276,000	$2,170,000	$15,650,000
Research and development	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation expense	335,000	248,000	865,000	756,000	'
General and administrative	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation expense	$1,473,000	$571,000	$2,411,000	$1,414,000	'

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares	'
Beginning Balance	3,539,961
Granted	425,426
Exercised	-156,349
Options forfeited/cancelled	-302,041
Ending Balance	3,507,005
Weighted Average Exercise Price	'
Beginning Balance	$5.66
Granted	$3.89
Exercised	$1.69
Options forfeited/cancelled	$17.16
Ending Balance	$4.59

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 26, 2013	Sep. 30, 2013
					Stock Options	Stock Options
						Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Unrecognized compensation cost	$5,086,000	'	$5,086,000	'	'	'
Unvested option	1,515,137	'	1,515,137	'	'	'
Unrecognized compensation cost, recognition period	'	'	'4 years 2 months 12 days	'	'	'
Weighted-average grant-date fair values of options granted	$3.55	$1.89	$3.17	$1.72	'	'
Shares authorized to be exercised	'	'	'	'	103,158	'
Stock options expiration period	'	'	'	'	'	'3 months
Non-cash charge related to modification	'	'	'	'	'	$930,000

Weighted_Average_Assumptions_U

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)	9 Months Ended	159 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	1.17%	1.75%
Expected life of the options	'5 years 3 months 18 days	'5 years 2 months 12 days
Expected volatility of the underlying stock	115.00%	119.00%
Expected dividend rate	0.00%	0.00%

Common_Stock_Warrant_Activity_

Common Stock Warrant Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares	'
Outstanding, December 31, 2012	7,424,241
Granted	5,000
Exercised	-831,212
Forfeited/cancelled	-50,000
Outstanding, September 30, 2013	6,548,029
Weighted Average Exercise Price	'
Outstanding, December 31, 2012	$3.71
Granted	$2.65
Exercised	$4.17
Forfeited/cancelled	$3
Outstanding, September 30, 2013	$3.65

Common_Stock_Warrants_Addition

Common Stock Warrants - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

159 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Mar. 22, 2012

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

6-May-13

6-May-13

Jan. 31, 2013

Warrants

Warrants

Before Modification

Before Modification

Before Modification

Before Modification

Before Modification

Before Modification

After Modification

After Modification

After Modification

After Modification

After Modification

After Modification

Class B Warrants

Class A-2 Warrants

Warrant

Minimum

Minimum

Maximum

Maximum

Minimum

Minimum

Maximum

Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Class B warrants having cashless exercise rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

Warrants for purchase common stock shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

Warrants exercisable life extended period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

Expense related to extension of warrants

'

$8,763,000

'

$8,763,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants required for extensions

'

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'5 years 3 months 18 days

'

'5 years 2 months 12 days

'

'

'

'9 months 7 days

'9 months 7 days

'2 years 4 days

'2 years 4 days

'

'

'5 years 9 months 11 days

'5 years 9 months 11 days

'7 years 7 days

'7 years 7 days

'

'

'3 years

Volatility rate,minimum

'

'

'

'

'

'

'

'

77.00%

77.00%

'

'

'

'

113.00%

113.00%

'

'

'

'

'

'

'

Volatility rate,maximum

'

'

'

'

'

'

'

'

96.00%

96.00%

'

'

'

'

122.00%

122.00%

'

'

'

'

'

'

'

Risk free interest,minimum

'

'

'

'

'

'

'

'

0.11%

0.11%

'

'

'

'

0.74%

0.74%

'

'

'

'

'

'

'

Risk free interest,maximum

'

'

'

'

'

'

'

'

0.22%

0.22%

'

'

'

'

1.19%

1.19%

'

'

'

'

'

'

'

Expected dividend payment

'

'

'

'

'

'

'

'

0

0

'

'

'

'

0

0

'

'

'

'

'

'

'

Warrants to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

Exercise price of warrant

'

'

'

'

'

'

'

5.63

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.65

Expected volatility of the underlying stock

'

'

'

'

115.00%

'

119.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87.00%

Risk-free interest rate

'

'

'

'

1.17%

'

1.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.42%

Expected dividend rate

'

'

'

'

0.00%

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

Stock-based compensation expense

$1,808,000

'

$819,000

'

$3,276,000

$2,170,000

$15,650,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,000

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments - Additional Information (Detail) (Money market funds, Fair Value, Inputs, Level 2, USD $)	Sep. 30, 2013	Dec. 31, 2012
Money market funds | Fair Value, Inputs, Level 2	'	'
Fair Value of Financial Instruments [Line Items]	'	'
Fair value of cash and cash equivalents invested in money market funds	$0	$583,000

Dilutive_Shares_Which_Could_Ex

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Dilutive shares not included in calculation	12,673,806	13,592,981
Warrant	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Dilutive shares not included in calculation	6,548,029	7,424,241
Stock Options	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Dilutive shares not included in calculation	3,507,005	3,541,630
Contingently Issuable Shares	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Dilutive shares not included in calculation	2,618,772	2,627,110

Common_Stock_and_Warrant_Offer1

Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) (USD $)	1 Months Ended			9 Months Ended		159 Months Ended		1 Months Ended
	Mar. 22, 2012	Mar. 23, 2012	Mar. 28, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Aug. 16, 2013	Mar. 28, 2012	Mar. 28, 2012
								Private Placement	Warrant one	Warrant two
Stockholders Equity [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock issued, shares	1,159,445	'	1,333,361	'	'	'	'	'	'	'
Common share issued per unit	2	'	'	'	'	'	'	'	'	'
Warrant to purchase common stock	1	'	'	'	'	'	'	'	'	'
Option to purchase additional units to cover over-allotments	'45 days	'	'	'	'	'	'	'	'	'
Additional units authorize for issuance	173,916	'	'	'	'	'	'	'	'	'
Public Offering price	$9	'	'	'	'	'	'	'	'	'
Exercise price of warrant	5.63	'	'	'	'	'	'	'	'	5.63
Expiration date of warrant	28-Mar-17	'	'	'	'	'	'	'	'	2-May-16
Issuance of common stock and warrants	'	'	2,666,722	'	'	'	'	'	'	'
Price per share of warrants	'	'	'	'	'	'	'	'	$5.63	'
Warrants to purchase shares of common stock	'	'	'	'	'	'	'	'	1,333,361	46,378
Gross proceeds from issuance of stock and warrants	'	'	$12,000,000	'	'	'	'	'	'	'
Net proceeds from issuance of stock and warrants	'	'	10,403,000	'	'	'	'	'	'	'
Value of warrants	'	'	'	'	'	'	'	'	4,445,000	143,000
Closing price of warrant issued	'	'	'	'	'	'	'	'	$4.20	$4.20
Warrant, expected life	'	'	'	'	'	'	'	'	'5 years	'4 years 1 month 6 days
Warrant, volatility rate	'	'	'	'	'	'	'	'	119.00%	117.00%
Warrant, risk free interest rate	'	'	'	'	'	'	'	'	1.05%	0.78%
Reverse stock split ratio	'	0.1667	'	'	'	'	'	'	'	'
Common stock, issued	'	'	'	17,650,977	'	17,650,977	16,060,853	500,000	'	'
Net proceeds from issuance of common stock	'	'	'	$3,000,000	$10,403,000	$42,093,000	'	$3,000,000	'	'

Commitments_Contingencies_and_1

Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

8 Months Ended

1 Months Ended

1 Months Ended

Jan. 31, 2013

Feb. 01, 2013

Oct. 31, 2012

31-May-12

Feb. 28, 2009

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Aug. 31, 2013

Feb. 01, 2013

Sep. 30, 2013

Jan. 31, 2013

Sep. 30, 2013

Jan. 31, 2013

Jan. 31, 2013

Jan. 31, 2013

Feb. 28, 2009

Right

Right

Subsequent Event

Drug Discovery Program with the University of Georgia

Drug Discovery Program with the University of Georgia

Series C super dividend convertible preferred stock

Series C super dividend convertible preferred stock

Common Stock

Common Stock

Common Stock

Minimum

Principal shares

Accrued Interest

Commitments and Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Service agreement expiration date

'

'

'

'

'

'

31-Jan-18

'

'

'

'

'

'

'

'

'

'

Estimated budget for work order

'

$2,155,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognized expenses related to agreement for services performed

'

'

'

'

'

239,000

1,329,000

'

'

'

'

'

'

'

'

'

'

Agreement termination notice period

'

'90 days

'

'

'

'

'

'

'

'90 days

'

'

'

'

'

'

'

Breach of contract termination notice period

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative funding agreement

'

'

'

'

'

'

'

'

'

154,000

'

'

'

'

'

'

'

Agreement related payment

'

'

'

'

'

'

'

'

'

'

154,000

'

'

'

'

'

'

Severance payment due to Dr. Platt

'

'

'

'

1,000,000

1,000,000

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

Cashless stock option exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Number of options vested

'

'

'

'

83,334

'

'

'

'

'

'

'

'

'

'

'

'

Equity investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

Royalty revenue

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Cashless stock option exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

Market capitalization

'

'

'

'

100,000,000

'

'

'

100,000,000

'

'

'

'

'

'

'

'

Severance payment period

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

Separation based payments

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Lawsuit payment

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series C prefer stock converted to common stock

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

Conversion of share, common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

8,475

8,334

141

'

Dividend rights issued

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate of dividend

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Dividend Rights

'

'

'

'

'

10

10

'

'

'

'

'

'

'

'

'

'

Redemption value of dividend rights

'

'

'

'

'

$241,000

$241,000

'

'

'

'

'

$5,013,000

'

'

'

'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended		9 Months Ended		159 Months Ended	1 Months Ended
	Mar. 22, 2012	Mar. 28, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Oct. 25, 2013	Nov. 01, 2013	Oct. 16, 2013
						Subsequent Event	Subsequent Event	Subsequent Event
						At Market Agreement	Class A-2 Warrants	Class A-2 Warrants
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Stock purchase warrants exercised	'	'	'	'	'	'	200,000	300,000
Exercise price of warrants	5.63	'	'	'	'	'	3	'
Proceeds from issuance of equity	'	$10,403,000	'	'	'	'	$1,500,000	'
Aggregate offering price	'	'	'	'	'	30,000,000	'	'
Commission rate as a percentage of gross proceeds	'	'	'	'	'	3.00%	'	'
Common stock, issued	1,159,445	1,333,361	'	'	'	50,643	'	'
Average share price	'	'	'	'	'	$10.82	'	'
Net proceeds from issuance of common stock	'	'	$3,000,000	$10,403,000	$42,093,000	$531,000	'	'